INZY vs. NLTX, CTNM, AQST, RANI, ENTA, XERS, CRMD, VTYX, MGNX, and NATR
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Neoleukin Therapeutics (NLTX), Contineum Therapeutics (CTNM), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), Enanta Pharmaceuticals (ENTA), Xeris Biopharma (XERS), CorMedix (CRMD), Ventyx Biosciences (VTYX), MacroGenics (MGNX), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
Inozyme Pharma (NASDAQ:INZY) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Inozyme Pharma currently has a consensus target price of $17.00, suggesting a potential upside of 269.57%. Given Inozyme Pharma's higher possible upside, research analysts clearly believe Inozyme Pharma is more favorable than Neoleukin Therapeutics.
In the previous week, Inozyme Pharma had 2 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 2 mentions for Inozyme Pharma and 0 mentions for Neoleukin Therapeutics. Inozyme Pharma's average media sentiment score of 0.31 beat Neoleukin Therapeutics' score of 0.00 indicating that Inozyme Pharma is being referred to more favorably in the media.
Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics received 15 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 81.40% of users gave Inozyme Pharma an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Inozyme Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
Neoleukin Therapeutics' return on equity of -37.22% beat Inozyme Pharma's return on equity.
88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 11.9% of Inozyme Pharma shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Inozyme Pharma beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
